Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy

Redefining dose-limiting toxicity.

Thrombotic microangiopathy associated with Valproic acid toxicity

BACKGROUND Thrombotic microangiopathy (TMA) is a serious, sometimes life-threatening disorder marked by the presence of endothelial injury and microvascular thrombi. Drug-induced thrombotic microangiopathy (DI-TMA) is one specific TMA syndrome that occurs following drug exposure via drug-dependent antibodies or direct tissue toxicity. Common examples include calcineurin inhibitors Tacrolimus an...

high dose methotrexat liver toxicity

introduction : methotrexate (mtx) is an anti folate drug that used in malignant and non malignant patients. the usage of high dose methotrexate was limited to patients with: osteogenic sarcoma, ewing sarcoma and lymphoma. the aim this study was to determine the toxicity or side effects of very high dose methotrexate (8-10 gr/m 2 /cycle). this study is the first study in iranian patients and one...

Sequential High Dose Chemotherapy and Stem Cell Rescue Versus Conventional Dose Chemotherapy for Stage III Breast Cancer

The purpose of this study is to determine if there is any benefit in disease-free survival (DFS) at 5 years of Stage III breast cancer patients who are treated with 2 sequential regimens of high-dose chemotherapy and peripheral blood stem cell (PBSC) transplant when compared with patients receiving conventional dose chemotherapy. Breast cancer affects 1in 8 women in the United States. 10-25% of...

Renal-limited thrombotic microangiopathy and acute interstitial nephritis with a single dose of quinine

Quinine has been reported to cause acute kidney injury by various mechanisms. The response to quinine can result in a spectrum of problems ranging from isolated thrombocytopenia to thrombotic microangiopathy (TMA) to disseminated intravascular coagulation. Quinine has also been reported to cause acute interstitial nephritis (AIN). We report an unusual presentation where both of these entities o...